Mirat Shah

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer”.

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0991

N/A

2.9DataRank · unranked

108 citations

Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah +20 more

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2599

N/A

0DataRank · unranked

23 citations

Preeti Narayan, Gwynn Ison, Tara Berman, Daniel L. Suzman, Suparna Wedam +18 more

Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes

Clinical Breast Cancer(2021)10.1016/j.clbc.2021.12.007

N/A

0DataRank · unranked

15 citations

Neha Mangini, John H. Fetting, Deborah K. Armstrong, Isaac S. Chan, Roisín M. Connolly +13 more

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2600

N/A

0DataRank · unranked

72 citations

Preeti Narayan, Christy Osgood, Suparna Wedam, Tatiana M. Prowell, Jennifer Gao +17 more

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1388

N/A

0DataRank · unranked

13 citations

Mirat Shah, Lijun Zhang, Joyce Cheng, Mary Kate Bonner, Melissa A. Pegues +22 more

Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology

Journal of Clinical Oncology(2025)10.1200/jco-25-00488

N/A

0DataRank · unranked

6 citations

Mirat Shah, Mark J. Ratain, Elizabeth Garrett‐Mayer, Atiqur Rahman, Marc R. Theoret +2 more

Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4325

N/A

0DataRank · unranked

1 citations

Nicole Drezner, Stacy S. Shord, Mirat Shah, Marc R. Theoret, Martha Donoghue +1 more